| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2125.2009.03566.X |
| P856 | official website | http://europepmc.org/articles/pmc2829696?pdf=render |
| P932 | PMC publication ID | 2829696 |
| P698 | PubMed publication ID | 20233197 |
| P5875 | ResearchGate publication ID | 42108280 |
| P2093 | author name string | James M Cook | |
| James M. Cook | |||
| Cyprian O Onyeji | |||
| Julius O Soyinka | |||
| Adegbenga R Owolabi | |||
| Pullela V Sarma | |||
| Sharon I Omoruyi | |||
| Adegbenga R. Owolabi | |||
| Cyprian O. Onyeji | |||
| Julius O. Soyinka | |||
| Pullela V. Sarma | |||
| Sharon I. Omoruyi | |||
| P2860 | cites work | Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450 | Q28299605 |
| Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers | Q28367567 | ||
| Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review | Q33377574 | ||
| Population pharmacokinetics of intramuscular quinine in children with severe malaria | Q33982327 | ||
| Interactions among drugs for HIV and opportunistic infections | Q34198731 | ||
| Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria | Q34358656 | ||
| The reproducibility of quinine bioavailability | Q34403728 | ||
| Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. | Q34732938 | ||
| Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations | Q34738805 | ||
| Pharmacokinetic interaction between ritonavir and clarithromycin | Q34754557 | ||
| Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects | Q35135626 | ||
| Practical guidelines to interpret plasma concentrations of antiretroviral drugs | Q35929973 | ||
| Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography | Q39253730 | ||
| Disposition of oral quinine in acute falciparum malaria | Q39499380 | ||
| Quinine for the treatment of chloroquine-resistant Plasmodium falciparum malaria in pregnant and non-pregnant Sudanese women | Q41912122 | ||
| Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. | Q44121796 | ||
| Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects | Q44167285 | ||
| Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues | Q44409239 | ||
| Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats | Q45213592 | ||
| Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure | Q45339891 | ||
| Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. | Q45738700 | ||
| Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics | Q46055776 | ||
| Simultaneous liquid chromatographic analysis of ritonavir, quinine and 3-hydroxyquinine in human plasma | Q46160890 | ||
| HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa | Q46538463 | ||
| Pharmacokinetics of quinine in African patients with acute falciparum malaria | Q46978707 | ||
| Binding of quinine to plasma proteins in falciparum malaria | Q47926996 | ||
| Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans. | Q50675901 | ||
| Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. | Q52534774 | ||
| Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. | Q52553124 | ||
| Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. | Q53964339 | ||
| Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. | Q64914976 | ||
| The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin | Q74541513 | ||
| Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents | Q77542483 | ||
| Grapefruit juice has no effect on quinine pharmacokinetics | Q78155675 | ||
| Metabolism of quinine | Q79464756 | ||
| Increased uptake of quinine into the brain by inhibition of P-glycoprotein | Q80795205 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| ritonavir | Q422618 | ||
| P304 | page(s) | 262-270 | |
| P577 | publication date | 2010-01-01 | |
| 2010-03-01 | |||
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| ??? | http://www.wikidata.org/.well-known/genid/1e00bccaa0722a34d6bc645922860c52 | ||
| P1476 | title | Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration | |
| P478 | volume | 69 |
| Q38513275 | A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products |
| Q45907681 | Antimalarial interaction of quinine and quinidine with clarithromycin. |
| Q34233691 | Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity |
| Q36320042 | Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection |
| Q48006398 | Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine |
| Q93495207 | Errata |
| Q39509379 | Expression of Organic Anion Transporting Polypeptide 1A2 in Red Blood Cells and Its Potential Impact on Antimalarial Therapy |
| Q37962449 | Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs. |
| Q42046734 | Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases |
| Q34404275 | Interactions between malaria and human immunodeficiency virus anno 2014 |
| Q38042679 | Multidrug and toxin extrusion proteins as transporters of antimicrobial drugs |
| Q28542863 | Neither the HIV protease inhibitor lopinavir-ritonavir nor the antimicrobial trimethoprim-sulfamethoxazole prevent malaria relapse in plasmodium cynomolgi-infected non-human primates |
| Q38813488 | Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. |
| Q36359372 | Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults |
| Q92219712 | Pharmacokinetic Parameters of Quinine in Healthy Subjects and in Patients with Uncomplicated Malaria in Nigeria: Analysis of Data using a Population Approach |
| Q58073610 | Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective |
| Q91265586 | Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir |
| Q42643524 | Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates |
| Q17485067 | Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria |
| Q38831370 | Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine |
| Q36504556 | The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa |
| Q28730788 | The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment |
Search more.